182 related articles for article (PubMed ID: 11807001)
41. Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells.
Yu CR; Young HA; Ortaldo JR
J Leukoc Biol; 1998 Aug; 64(2):245-58. PubMed ID: 9715265
[TBL] [Abstract][Full Text] [Related]
42. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
43. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
44. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
45. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
46. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.
Gluud M; Pallesen EMH; Buus TB; Gjerdrum LMR; Lindahl LM; Kamstrup MR; Bzorek M; Danielsen M; Bech R; Monteiro MN; Blümel E; Willerslev-Olsen A; Lykkebo-Valløe A; Vadivel CK; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Koralov SB; Iversen L; Litman T; Woetmann A; Ødum N
Blood; 2023 Jan; 141(2):180-193. PubMed ID: 36122387
[TBL] [Abstract][Full Text] [Related]
47. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
[TBL] [Abstract][Full Text] [Related]
48. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.
Verma NK; Davies AM; Long A; Kelleher D; Volkov Y
Cell Mol Biol Lett; 2010 Jun; 15(2):342-55. PubMed ID: 20213502
[TBL] [Abstract][Full Text] [Related]
49. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Witkiewicz A; Raghunath P; Wasik A; Junkins-Hopkins JM; Jones D; Zhang Q; Odum N; Wasik MA
Hum Pathol; 2007 Mar; 38(3):462-7. PubMed ID: 17239936
[TBL] [Abstract][Full Text] [Related]
50. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
51. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements.
Lai CF; Ripperger J; Morella KK; Jurlander J; Hawley TS; Carson WE; Kordula T; Caligiuri MA; Hawley RG; Fey GH; Baumann H
J Biol Chem; 1996 Jun; 271(24):13968-75. PubMed ID: 8662928
[TBL] [Abstract][Full Text] [Related]
52. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
53. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.
Wolk K; Mitsui H; Witte K; Gellrich S; Gulati N; Humme D; Witte E; Gonsior M; Beyer M; Kadin ME; Volk HD; Krueger JG; Sterry W; Sabat R
Clin Cancer Res; 2014 Nov; 20(21):5507-16. PubMed ID: 25212608
[TBL] [Abstract][Full Text] [Related]
54. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
55. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.
Krejsgaard T; Willerslev-Olsen A; Lindahl LM; Bonefeld CM; Koralov SB; Geisler C; Wasik MA; Gniadecki R; Kilian M; Iversen L; Woetmann A; Odum N
Blood; 2014 Jul; 124(5):761-70. PubMed ID: 24957145
[TBL] [Abstract][Full Text] [Related]
56. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
[TBL] [Abstract][Full Text] [Related]
57. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
[TBL] [Abstract][Full Text] [Related]
58. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells.
Nagalakshmi ML; Rascle A; Zurawski S; Menon S; de Waal Malefyt R
Int Immunopharmacol; 2004 May; 4(5):679-91. PubMed ID: 15120652
[TBL] [Abstract][Full Text] [Related]
59. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.
Döbbeling U; Waeckerle-Men Y; Zabel F; Graf N; Kündig TM; Johansen P
Exp Dermatol; 2013 Feb; 22(2):119-24. PubMed ID: 23362870
[TBL] [Abstract][Full Text] [Related]
60. NLRP3 Regulates IL-4 Expression in TOX
Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
Front Immunol; 2021; 12():668369. PubMed ID: 34220814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
